Norbert Gattermann

15.9k citations
256 papers · 7.3k · 1 hit paper · h-index 44

Impact in

  • Hematology top 0.05%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 0.1%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Hemoglobinopathies and Related Disorders

Papers in

    • Acute Myeloid Leukemia Research 151
    • Chronic Myeloid Leukemia Treatments 50
    • Hematopoietic Stem Cell Transplantation 16
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 50
    • Chronic Lymphocytic Leukemia Research 48
    • Hemoglobinopathies and Related Disorders 38

Norbert Gattermann

240 papers receiving 7.1k citations

Norbert Gattermann's Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance 2007 · 542 citations
5420+6+12Years since publication100200300400500

Peers

Norbert Gattermann
Comparison fields: 5 of 115
  • Hematology 5.4k
  • Genetics 3.1k
  • Rheumatology 895
  • Emergency Medicine 340
  • Molecular Biology 1.9k
Replace Luca Malcovati with:
Luca Malcovati Italy
Rosangela Invernizzi Italy
Mary Frances McMullin United Kingdom
Thomas Illmer Germany
David Bowen United Kingdom
David Grimwade United Kingdom
Markus Schaich Germany
Michael Heuser Germany
Paresh Vyas United Kingdom
Felicetto Ferrara Italy
Norbert Gattermann relative to Luca Malcovati Italy Luca Malcovati's profile →
Citations per field
00.5×2.7×
Luca Malcovati · 1×
Citations per year

Countries citing papers authored by Norbert Gattermann

Since Specialization
Citations

This map shows the geographic impact of Norbert Gattermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Gattermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Gattermann more than expected).

Fields of papers citing papers by Norbert Gattermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Gattermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Gattermann. The network helps show where Norbert Gattermann may publish in the future.

Co-authors

The 25 scholars most cited alongside Norbert Gattermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norbert Gattermann Line = papers co-authored together Norbert Gattermann links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 256 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hit paper breakdown →
2007542
2 2010273
3 2009234
4
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
1992210
5 2017209
6 2000206
7 2004194
8 2005189
9 2012180
10 2013177
11 2010175
12 1992165
13 2005128
14 1997121
15 1997120
16 2002118
17 2007113
18 1998112
19 2002112
20 2018106

About Norbert Gattermann

Norbert Gattermann is a scholar working on Hematology, Genetics, Molecular Biology, Rheumatology and Oncology, having authored 256 papers that have together received 7.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (151 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (50 papers), Chronic Myeloid Leukemia Treatments (50 papers), Chronic Lymphocytic Leukemia Research (48 papers), Hemoglobinopathies and Related Disorders (38 papers), Eosinophilic Disorders and Syndromes (18 papers), Histone Deacetylase Inhibitors Research (17 papers) and Hematopoietic Stem Cell Transplantation (16 papers). The work is most often cited by research in Hematology (5.4k citations), Genetics (3.1k citations), Rheumatology (895 citations), Emergency Medicine (340 citations) and Molecular Biology (1.9k citations). Norbert Gattermann has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Ulrich Germing, Rainer Haas, Carlo Aul, Corinna Strupp, Ulrich Germing, Wolfgang Schneider, Manuel Aivado, Barbara Hildebrandt, Andreas Hochhaus and Francis J. Giles. Their work appears in journals such as Blood, Leukemia Research, Annals of Hematology, Journal of Clinical Oncology and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact